Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Evdakiya Deiner

Nurse Practitioner Sebastian, FL Nurse Practitioner

NPI 1457755795 CMS profile 10418944

484 US Highway 1 Ste C, Sebastian, FL 32958

Open in the dashboard

General payments

$6,113

245 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Evdakiya Deiner of Sebastian, FL is reported in the CMS Open Payments database as having received $6,113 across 245 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,155 44
2024 General $1,219 48
2023 General $1,704 59
2022 General $900 44
2021 General $1,135 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Evdakiya Deiner
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Evdakiya Deiner were reported at $1,155. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Evdakiya Deiner Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,135 $135 $40–$426 $132
2022 $900 $152 $48–$470 $149
2023 $1,704 $166 $54–$529 $160
2024 $1,219 $173 $55–$556 $164
2025 $1,155 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,263 37 payments
  2. Janssen Biotech, Inc. $1,090 64 payments
  3. Galderma Laboratories, L.P. $464 19 payments
  4. Regeneron Healthcare Solutions, Inc. $454 12 payments
  5. Novartis Pharmaceuticals Corporation $345 16 payments
  6. Dermavant Sciences, Inc. $329 12 payments
  7. Incyte Corporation $250 7 payments
  8. Lilly USA, LLC $244 10 payments
  9. UCB, Inc. $205 4 payments
  10. E.R. Squibb & Sons, L.L.C. $148 7 payments
  11. Other $1,321 57 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,923 243 payments
  2. Education $190 2 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $976 52 payments
  2. BOTOX $413 6 payments
  3. VTAMA $329 12 payments
  4. SKYRIZI $296 12 payments
  5. DUPIXENT $294 7 payments
  6. OPZELURA $250 7 payments
  7. COSENTYX $220 10 payments
  8. TALTZ $218 9 payments
  9. Bimzelx $205 4 payments
  10. AKLIEF $186 8 payments
  11. Other $3,438 154 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

939

Median for Nurse Practitioner: 389

Drug cost

$86,594

Median for Nurse Practitioner: $21,885

Branded share of claims

7.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 17 $62,173
Fluorouracil Generic 184 $12,199
Clobetasol Propionate Generic 130 $4,144
Ketoconazole Generic 158 $2,364
Permethrin Generic 15 $1,062
Doxycycline Hyclate Generic 90 $898
Econazole Nitrate Generic 24 $825
Metronidazole Generic 14 $652
Triamcinolone Acetonide Generic 99 $539
Ciclopirox Generic 18 $445

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$196,415

Of which drugs: $16,418

Medicare patients

787

Average age 76

Services billed

4,905

437 women, 350 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 48%
Ischemic heart disease 27%
Diabetes 21%
Chronic kidney disease 19%
Osteoporosis 19%
Atrial fibrillation 18%
Cancer 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 36 54 $16,398

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $321
$321 — —
AKLIEF
  • Galderma Laboratories, L.P. $149
$149 — —
SKYRIZI
  • AbbVie, Inc. $129
$129 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $94
$94 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $58
  • GENZYME CORPORATION $29
$86 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

245 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record